| 1 |
35443750 | The BCL-2 inhibitor ABT-199/venetoclax synergizes with proteasome inhibition via transactivation of the MCL-1 antagonist NOXA. | 2022 Apr 20 |
2 |
| 2 |
34133998 | Verticillin A increases the BIMEL/MCL-1 ratio to overcome ABT-737-resistance in human colon cancer cells by targeting the MEK/ERK pathway. | 2021 Aug 27 |
1 |
| 3 |
34257274 | Bcl-2/Bcl-xL inhibitor ABT-263 overcomes hypoxia-driven radioresistence and improves radiotherapy. | 2021 Jul 13 |
1 |
| 4 |
34336680 | The Basic Research of the Combinatorial Therapy of ABT-199 and Homoharringtonine on Acute Myeloid Leukemia. | 2021 |
2 |
| 5 |
34439278 | Photodynamic Therapy Combined with Bcl-2/Bcl-xL Inhibition Increases the Noxa/Mcl-1 Ratio Independent of Usp9X and Synergistically Enhances Apoptosis in Glioblastoma. | 2021 Aug 17 |
1 |
| 6 |
31669390 | Using CETSA assay and a mathematical model to reveal dual Bcl-2/Mcl-1 inhibition and on-target mechanism for ABT-199 and S1. | 2020 Jan 15 |
2 |
| 7 |
32212793 | Gene Therapy with MiRNA-Mediated Targeting of Mcl-1 Promotes the Sensitivity of Non-Small Cell Lung Cancer Cells to Treatment with ABT-737. | 2020 Mar 1 |
2 |
| 8 |
32346617 | Co-inhibition of BCL-XL and MCL-1 with selective BCL-2 family inhibitors enhances cytotoxicity of cervical cancer cell lines. | 2020 Jul |
1 |
| 9 |
33020573 | Berberine affects mitochondrial activity and cell growth of leukemic cells from chronic lymphocytic leukemia patients. | 2020 Oct 5 |
1 |
| 10 |
33218059 | Melatonin Can Modulate the Effect of Navitoclax (ABT-737) in HL-60 Cells. | 2020 Nov 18 |
1 |
| 11 |
29924730 | Selective BH3-mimetics targeting BCL-2, BCL-XL or MCL-1 induce severe mitochondrial perturbations. | 2019 Jan 28 |
1 |
| 12 |
30224339 | NOTCH1 Represses MCL-1 Levels in GSI-resistant T-ALL, Making them Susceptible to ABT-263. | 2019 Jan 1 |
1 |
| 13 |
30320607 | Co-operation of ABT-199 and gemcitabine in impeding DNA damage repair and inducing cell apoptosis for synergistic therapy of T-cell acute lymphoblastic leukemia. | 2019 Feb |
1 |
| 14 |
30374681 | Rationally derived drug combinations with the novel Mcl-1 inhibitor EU-5346 in breast cancer. | 2019 Feb |
1 |
| 15 |
30470795 | Impact of elevated anti-apoptotic MCL-1 and BCL-2 on the development and treatment of MLL-AF9 AML in mice. | 2019 Jul |
4 |
| 16 |
30626241 | MCL-1 or BCL-xL-dependent resistance to the BCL-2 antagonist (ABT-199) can be overcome by specific inhibitor as single agents and in combination with ABT-199 in acute myeloid leukemia cells. | 2019 Sep |
2 |
| 17 |
30663221 | The Ibr-7 derivative of ibrutinib exhibits enhanced cytotoxicity against non-small cell lung cancer cells via targeting of mTORC1/S6 signaling. | 2019 Apr |
1 |
| 18 |
30679640 | Off-target based drug repurposing opportunities for tivantinib in acute myeloid leukemia. | 2019 Jan 24 |
1 |
| 19 |
30728900 | Optimal targeting of BCL-family proteins in head and neck squamous cell carcinoma requires inhibition of both BCL-xL and MCL-1. | 2019 Jan 11 |
1 |
| 20 |
30949409 | Targeting sphingosine kinase 2 suppresses cell growth and synergizes with BCL2/BCL-XL inhibitors through NOXA-mediated MCL1 degradation in cholangiocarcinoma. | 2019 |
1 |
| 21 |
31127149 | Imipridone ONC212 activates orphan G protein-coupled receptor GPR132 and integrated stress response in acute myeloid leukemia. | 2019 Dec |
1 |
| 22 |
28947136 | BCL-xL-selective BH3 mimetic sensitizes rhabdomyosarcoma cells to chemotherapeutics by activation of the mitochondrial pathway of apoptosis. | 2018 Jan 1 |
1 |
| 23 |
29241222 | Flavopiridol enhances ABT-199 sensitivity in unfavourable-risk multiple myeloma cells in vitro and in vivo. | 2018 Feb 6 |
1 |
| 24 |
29343814 | Intrinsic apoptotic pathway activation increases response to anti-estrogens in luminal breast cancers. | 2018 Jan 17 |
1 |
| 25 |
29682179 | Antiapoptotic BCL-2 proteins determine sorafenib/regorafenib resistance and BH3-mimetic efficacy in hepatocellular carcinoma. | 2018 Mar 30 |
1 |
| 26 |
29858601 | BCL-2 selective inhibitor ABT-199 primes rhabdomyosarcoma cells to histone deacetylase inhibitor-induced apoptosis. | 2018 Sep |
2 |
| 27 |
29913235 | ABT-263-induced MCL1 upregulation depends on autophagy-mediated 4EBP1 downregulation in human leukemia cells. | 2018 Sep 28 |
7 |
| 28 |
30250075 | Sensitizing non-small cell lung cancer to BCL-xL-targeted apoptosis. | 2018 Sep 24 |
1 |
| 29 |
28038464 | Mcl-1 expression and JNK activation induces a threshold for apoptosis in Bcl-xL-overexpressing hematopoietic cells. | 2017 Feb 14 |
5 |
| 30 |
28120212 | YM155 enhances ABT-737-mediated apoptosis through Mcl-1 downregulation in Mcl-1-overexpressed cancer cells. | 2017 May |
2 |
| 31 |
28950657 | The BET-Bromodomain Inhibitor JQ1 synergized ABT-263 against colorectal cancer cells through suppressing c-Myc-induced miR-1271-5p expression. | 2017 Nov |
3 |
| 32 |
28974549 | Modulation of Navitoclax Sensitivity by Dihydroartemisinin-Mediated MCL-1 Repression in BCR-ABL+ B-Lineage Acute Lymphoblastic Leukemia. | 2017 Dec 15 |
4 |
| 33 |
28987383 | HSP90 inhibitor (NVP-AUY922) enhances the anti-cancer effect of BCL-2 inhibitor (ABT-737) in small cell lung cancer expressing BCL-2. | 2017 Dec 28 |
1 |
| 34 |
29156797 | JQ1 synergizes with the Bcl-2 inhibitor ABT-263 against MYCN-amplified small cell lung cancer. | 2017 Oct 17 |
1 |
| 35 |
29263915 | Inhibition of Mcl-1 enhances cell death induced by the Bcl-2-selective inhibitor ABT-199 in acute myeloid leukemia cells. | 2017 |
4 |
| 36 |
29372687 | Cyclin-dependent kinase 2 inhibitor SU9516 increases sensitivity of colorectal carcinoma cells Caco-2 but not HT29 to BH3 mimetic ABT-737. | 2017 Dec |
1 |
| 37 |
26100943 | Knockdown of BAG3 sensitizes bladder cancer cells to treatment with the BH3 mimetic ABT-737. | 2016 Feb |
1 |
| 38 |
26467384 | Targeting of BCL2 Family Proteins with ABT-199 and Homoharringtonine Reveals BCL2- and MCL1-Dependent Subgroups of Diffuse Large B-Cell Lymphoma. | 2016 Mar 1 |
2 |
| 39 |
26493374 | Bcl-2 phosphorylation confers resistance on chronic lymphocytic leukaemia cells to the BH3 mimetics ABT-737, ABT-263 and ABT-199 by impeding direct binding. | 2016 Feb |
3 |
| 40 |
26515494 | A Novel Bioavailable BH3 Mimetic Efficiently Inhibits Colon Cancer via Cascade Effects of Mitochondria. | 2016 Mar 15 |
1 |
| 41 |
26704388 | Combination of galectin inhibitor GCS-100 and BH3 mimetics eliminates both p53 wild type and p53 null AML cells. | 2016 Apr |
1 |
| 42 |
26910119 | Inhibition of MARCH5 ubiquitin ligase abrogates MCL1-dependent resistance to BH3 mimetics via NOXA. | 2016 Mar 29 |
1 |
| 43 |
27095788 | BCR signaling inhibitors differ in their ability to overcome Mcl-1-mediated resistance of CLL B cells to ABT-199. | 2016 Jun 23 |
3 |
| 44 |
27103402 | Binding of Released Bim to Mcl-1 is a Mechanism of Intrinsic Resistance to ABT-199 which can be Overcome by Combination with Daunorubicin or Cytarabine in AML Cells. | 2016 Sep 1 |
10 |
| 45 |
27138804 | MCL-1 is the key target of adjuvant chemotherapy to reverse the cisplatin-resistance in NSCLC. | 2016 Aug 10 |
1 |
| 46 |
27166183 | Inhibition of CHK1 enhances cell death induced by the Bcl-2-selective inhibitor ABT-199 in acute myeloid leukemia cells. | 2016 Jun 7 |
1 |
| 47 |
27283158 | Targeting MCL-1/BCL-XL Forestalls the Acquisition of Resistance to ABT-199 in Acute Myeloid Leukemia. | 2016 Jun 10 |
5 |
| 48 |
27429848 | BH3 mimetic ABT-737 sensitizes colorectal cancer cells to ixazomib through MCL-1 downregulation and autophagy inhibition. | 2016 |
2 |
| 49 |
27460078 | VHL-deficient renal cancer cells gain resistance to mitochondria-activating apoptosis inducers by activating AKT through the IGF1R-PI3K pathway. | 2016 Oct |
3 |
| 50 |
27480872 | Correction: Targeting of BCL2 Family Proteins with ABT-199 and Homoharringtonine Reveals BCL2- and MCL1-Dependent Subgroups of Diffuse Large B-Cell Lymphoma. | 2016 Aug 1 |
1 |